The FDA has spent much of 2025 issuing warnings about a single, recurring problem with GLP-1 weight loss drugs: patients and providers are getting the dose wrong on compounded versions, and the consequences range from severe nausea and vomiting to hospitalization. As national shortages of brand-name semaglutide and tirzepatide ease, the agency is tightening enforcement on the compounded alternatives that millions of people turned to out of necessity. The result is a collision between access, cost, and safety that every current or prospective GLP-1 user needs to understand.
How Dosing Errors Became the Central Risk
The single biggest mistake people make with GLP-1 drugs is not choosing the wrong brand or skipping a dose. It is injecting the wrong amount of a compounded product because the math between milligrams, milliliters, and syringe units is genuinely confusing. The FDA issued a direct alert to providers and patients after receiving adverse-event reports tied to overdoses from compounded semaglutide multi-dose vials. Patients were using U-100 insulin syringes to measure very small volumes, and some prescribers miscalculated conversions from mg to mL or units.
The error is deceptively easy to make. Compounded semaglutide vials can come in varying concentrations, and unlike the pre-filled pens sold as Ozempic or Wegovy, they require the user or clinician to calculate the correct draw volume each time. A review by the University of Illinois Chicago Drug Information Group identified the core failure modes: mg-to-units conversion mistakes, inconsistent concentrations across compounders, and the inherent difficulty of measuring from multi-dose vials. That review also noted that adverse-event totals reported to the FDA through spring 2025 likely reflect significant underreporting, meaning the real scope of harm is almost certainly larger than official counts suggest.
Dosing errors are not limited to compounded products. The Utah Poison Control Center warned in January 2025 that overdoses occur with both prefilled products like Ozempic and Wegovy and with compounded GLP-1 formulations. But the compounded versions carry a steeper risk because every injection demands a fresh calculation rather than a click on a pre-set dial.
Why Patients Ended Up With Compounded Drugs
The backstory matters because it shapes the choices people face right now. When semaglutide and tirzepatide supply could not keep up with demand, the FDA exercised enforcement discretion that allowed compounding pharmacies to produce versions of these drugs. Patients turned to compounded GLP-1s primarily because of access and cost barriers during those shortages. As supply has begun to stabilize, the FDA has updated its policies for compounders and signaled it would tighten enforcement going forward.
That shift creates a new tension. Many patients who found affordable treatment through compounding pharmacies now face a choice: transition to brand-name drugs that can cost over $1,000 per month without insurance, or continue using compounded products under increasing regulatory scrutiny. The risk is that tighter enforcement, while justified on safety grounds, could push some patients to discontinue treatment altogether rather than absorb higher costs. And discontinuation carries its own well-documented dangers.
What Happens When People Stop
The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism, tracked what happened after participants stopped semaglutide 2.4 mg. In that analysis, people who discontinued therapy regained much of the weight they had lost, and cardiometabolic improvements moved back toward baseline. This is not a side effect of one particular formulation. It reflects the biology of GLP-1 receptor agonists as a drug class: they work while patients take them, and their benefits erode when patients stop.
That finding reframes the dosing-error problem in a broader way. The biggest mistake is not just getting the dose wrong on a single injection. It is making choices about sourcing, cost, and continuity that lead to either a dangerous overdose or an abrupt halt in treatment. Both paths carry real health consequences, and neither is theoretical.
Illegal Ingredients and the Supply Chain Problem
Beyond dosing math, the FDA has flagged a separate but related risk: the active ingredients themselves may not be what they claim to be. To address this, the agency launched a so‑called Green List to screen imported ingredients and protect Americans from illegal GLP‑1 drug components entering the supply chain. The initiative targets upstream problems where compounders or knockoff sellers might use active pharmaceutical ingredients sourced from unverified foreign manufacturers.
The FDA has also warned about the use of unapproved salt forms of semaglutide in compounded products and about dosing that goes beyond FDA-approved labeling. As of July 31, 2025, the agency published specific adverse-event counts for both compounded semaglutide and tirzepatide on its page for postmarket safety data related to semaglutide products. Those figures include hospitalizations and other serious outcomes linked to products marketed for type 2 diabetes or weight loss, underscoring that the risks are not hypothetical.
Regulators are also scrutinizing how these drugs are promoted. In a 2025 warning letter to Eli Lilly, the FDA cited the company over promotional claims for tirzepatide that, in the agency’s view, minimized risks and overstated benefits. The letter, which is publicly available among the FDA’s compliance actions, illustrates how closely officials are watching the entire GLP‑1 ecosystem (from raw ingredients and compounding practices to marketing by major manufacturers).
What Patients and Providers Can Do Now
For patients currently using or considering GLP‑1 drugs, the most practical step is to reduce preventable errors. That starts with clarity on exactly what product you are receiving and how to measure it. If you are using a compounded multi‑dose vial, ask your prescriber to write the dose in both milligrams and milliliters and to specify the syringe type. Do not rely on verbal instructions alone, and do not guess if the numbers on the syringe do not match the instructions.
Clinicians can lower risk by standardizing to a single concentration per practice when possible, providing written conversion charts, and scheduling a supervised first injection for any patient new to a compounded vial. Pharmacists can reinforce this by reviewing the dose and syringe markings at pickup. These simple redundancies mirror the safeguards used with high‑risk hospital medications, adapted to outpatient weight‑loss care.
Patients should also be cautious about sourcing drugs online or from medical spas that cannot clearly document where their active ingredients come from. Asking whether a product’s active ingredient is sourced through channels consistent with the FDA’s Green List framework will not guarantee safety, but it can help identify sellers operating entirely outside regulated supply chains.
How to Report Problems—and Why It Matters
One reason dosing risks and ingredient problems are hard to quantify is that many adverse events never reach regulators. The FDA encourages clinicians and patients to report serious side effects, product quality issues, and suspected counterfeit or illegally compounded products. Reports can be submitted through the federal safety reporting portal, which routes information to the appropriate agencies.
Filing a report does not replace medical care, but it does help regulators spot patterns more quickly, whether that is a particular compounder whose vials are mislabeled or a recurring type of dosing confusion tied to certain syringe instructions. Over time, those data points inform the safety alerts, enforcement decisions, and label changes that shape how GLP‑1 drugs are prescribed and dispensed.
Balancing Access, Cost, and Safety
The story of compounded GLP‑1 drugs in 2025 is not simply one of bad actors or careless patients. It is a case study in what happens when a breakthrough therapy meets limited supply, high prices, and enormous demand. Compounded products filled a gap when brand‑name semaglutide and tirzepatide were scarce, but they introduced new layers of risk, from dosing math to questionable ingredients, that regulators are now trying to unwind.
For individual patients, the safest path is rarely obvious or easy. Brand‑name pens offer standardized dosing and a clearer safety record but may be financially out of reach. Compounded vials can be more affordable and accessible but demand meticulous attention to concentration, syringe selection, and source quality. Stopping treatment altogether can reverse hard‑won health gains. Navigating those trade‑offs requires candid conversations with clinicians, careful reading of instructions, and a willingness to speak up, whether that means asking a pharmacist to re‑explain a dose or submitting a formal report when something seems wrong.
As the FDA continues to refine its enforcement posture and collect more data, the central message for users of GLP‑1 drugs remains straightforward: these medications can be powerful tools, but they are not simple. Getting the dose right, verifying the product, and maintaining safe, continuous treatment are now as critical to long‑term success as diet, exercise, and every other piece of a weight‑management plan.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
